A joint analysis performed on a validation cohort of 165 individuals (66 H, 41 AH, 19 EGC, and 39 advanced GC patients) confirmed that the proposed models discriminate EGC patients from H subjects using the combination of CEA + CA72-4 + IL-6 + IL-8 + TNFα, with a sensitivity of 84.21% and specificity of 90.91%, whilst the combination CA72-4 + IL-6 + IL-8 + TNFα, with a sensitivity of 78.95% and specificity of 85.37%, discriminated EGC patients from patients with AH. The gene discussed is IL6; the disease is gastric cancer.